3 Drugs Stocks Driving The Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 78 points (0.5%) at 17,023 as of Friday, Sept. 26, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,765 issues advancing vs. 1,183 declining with 200 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Shire ( SHPG), up 2.2%, Allergan ( AGN), up 1.2% and AstraZeneca ( AZN), up 1.0%. A company within the industry that fell today was Biogen Idec ( BIIB), up 1.3%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Sanofi ( SNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.28 (0.5%) to $56.13 on light volume. Thus far, 276,455 shares of Sanofi exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $55.90-$56.38 after having opened the day at $56.14 as compared to the previous trading day's close of $55.85.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Sanofi has a market cap of $150.4 billion and is part of the health care sector. Shares are up 4.1% year-to-date as of the close of trading on Thursday. Currently there are 3 analysts who rate Sanofi a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, reasonable valuation levels, compelling growth in net income and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Sanofi Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Vertex Pharmaceuticals ( VRTX) is up $3.00 (2.7%) to $113.28 on average volume. Thus far, 1.0 million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $110.92-$113.58 after having opened the day at $112.36 as compared to the previous trading day's close of $110.28.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals has a market cap of $26.7 billion and is part of the health care sector. Shares are up 48.4% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts who rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, unimpressive growth in net income and disappointing return on equity. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, AbbVie ( ABBV) is up $0.44 (0.8%) to $58.44 on average volume. Thus far, 8.4 million shares of AbbVie exchanged hands as compared to its average daily volume of 12.2 million shares. The stock has ranged in price between $58.10-$59.08 after having opened the day at $58.54 as compared to the previous trading day's close of $58.00.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $94.0 billion and is part of the health care sector. Shares are up 9.8% year-to-date as of the close of trading on Thursday. Currently there are 5 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates AbbVie as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and increase in net income. However, as a counter to these strengths, we also find weaknesses including weak operating cash flow and generally higher debt management risk. Get the full AbbVie Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss

Stocks Trade Lower as Optimism Wanes Over China Trade Talks

Stocks Trade Lower as Optimism Wanes Over China Trade Talks

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Comcast Considering All-Cash Bid for Fox as Disney Battle Heads to the Wire

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Target's Stock Tanks After Q1 Earnings Miss and Slowing Sales

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade

Global Rally Stalls as Trump Doubts North Korea Summit, Questions China Trade